A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
11/16/2023
Locations: Medical College of Wisconsin, Inc., Milwaukee, Wisconsin
Conditions: Alzheimer's Disease
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/03/2023
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 250 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
All
Ages:
Between 25 years and 55 years
Trial Updated:
10/21/2023
Locations: University of Wisconsin - Madison, Waisman Center, Co-Enrolling through ABC-DS Only, Madison, Wisconsin
Conditions: Down Syndrome, Alzheimer Disease, Dementia
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/18/2023
Locations: Spaulding Clinical Research, West Bend, Wisconsin
Conditions: Alzheimer's Disease
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
10/09/2023
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial).
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
06/27/2023
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Recruiting
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.
Gender:
Female
Ages:
Between 65 years and 120 years
Trial Updated:
05/30/2023
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions for Patients With Alzheimer's Disease and Dysphagia
Recruiting
The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.
Gender:
All
Ages:
Between 50 years and 99 years
Trial Updated:
05/10/2023
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Dementia, Dysphagia, Alzheimer Disease